ArticleRheumatology and therapy2022

Ixekizumab Demonstrates Consistent Efficacy Versus Adalimumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Psoriatic Arthritis Patients Regardless of Psoriasis Severity: 52-Week Post Hoc Results from SPIRIT-H2H.

Lars-Erik Kristensen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.